For the latest updates on our ongoing response to COVID-19, please click here.

Our Purpose


Science & Medicine

News and Press

Company Statements

Gilead Sciences Statement on the Solidarity Trial

Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations

Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines

Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network

Gilead Sciences Statement on State Attorneys General Letter on Remdesivir

Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19

Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19

Gilead Sciences Statement on Remdesivir Clinical Data

Gilead Sciences Response to U.S. Senators on Trial Diversity

Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study

Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

Gilead Sciences Response to Médecins Sans Frontières

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak

Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females

Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

Petitions to US Patent and Trademark Office on HIV PrEP Patents

Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

Grants for SCLAN

Authorized Generics For HCV

Discount For Ambisome

Gilead 2017 Year in Review

100 Corporate Equality Score

Emergency Disaster Response

Gilead Year in Review 2016

Top Corporate Philanthropist

HIV Medicines Reach 10 Million People

Discover Study Of FTAF For PrEP

Corporate Responsibility Report 2015

Gilead Supports PrEP Education

Corporate Contributions Report

Celebrating Transgender Awareness Week

Kite Pharma

Harnessing The Immune System



Global Operations